These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11778588)

  • 21. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.
    Wittes J; Barrett-Connor E; Braunwald E; Chesney M; Cohen HJ; Demets D; Dunn L; Dwyer J; Heaney RP; Vogel V; Walters L; Yusuf S
    Clin Trials; 2007; 4(3):218-34. PubMed ID: 17715247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rashomon revisited: two views of monitoring the Women's Health Initiative trials.
    Goodman SN
    Clin Trials; 2007; 4(3):205-6. PubMed ID: 17715245
    [No Abstract]   [Full Text] [Related]  

  • 24. Preliminary data release for randomized clinical trials of noninferiority: a new proposal.
    Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
    J Clin Oncol; 2005 Aug; 23(24):5831-6. PubMed ID: 16027441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strength of accumulating evidence and data monitoring committee decision making.
    George SL; Freidlin B; Korn EL
    Stat Med; 2004 Sep; 23(17):2659-72. PubMed ID: 15316949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When should an interim analysis be unblinded to the data monitoring committee?
    Knottnerus JA; Spigt MG
    J Clin Epidemiol; 2010 Apr; 63(4):350-2. PubMed ID: 19762210
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of the Data and Safety Monitoring Committee (DSMC).
    Wilhelmsen L
    Stat Med; 2002 Oct; 21(19):2823-9. PubMed ID: 12325098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striding forward or getting too big for their boots? The developing role of data monitoring committees in clinical trials.
    Tharmanathan P; Calvert MJ; Freemantle N
    J Clin Pharm Ther; 2006 Apr; 31(2):111-8. PubMed ID: 16635044
    [No Abstract]   [Full Text] [Related]  

  • 31. The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
    Anderson JR; Krailo M
    Am J Bioeth; 2011 Mar; 11(3):18-9. PubMed ID: 21400379
    [No Abstract]   [Full Text] [Related]  

  • 32. Institution/investigator-initiated clinical trials in Canada.
    Sedgeworth J; Derewlany L
    Can J Clin Pharmacol; 2006; 13(2):e236-9. PubMed ID: 16873897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal.
    Dechartres A; Boutron I; Roy C; Ravaud P
    J Clin Epidemiol; 2009 Jul; 62(7):695-702. PubMed ID: 19135860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Data monitoring (and safety) committees--what are they and why do we need them? Primary Care Alliance for Clinical Trials (PACT) Network.
    Pirotta M; Chondros P;
    Aust Fam Physician; 2004 Nov; 33(11):950-1, 956. PubMed ID: 15584339
    [No Abstract]   [Full Text] [Related]  

  • 35. [Monitoring the safety of participants in randomised clinical trials: basis and methods].
    Tijssen JG
    Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. More on data monitoring and large apparent treatment effects.
    Anderson JR
    Contemp Clin Trials; 2005 Jun; 26(3):416-7. PubMed ID: 15911475
    [No Abstract]   [Full Text] [Related]  

  • 37. IVF with preimplantation genetic screening, a promising new treatment with unexpectedly negative health outcomes: the Hippocratic role of Data Monitoring Committees.
    Ankum WM; Reitsma JB; Offringa M;
    Hum Reprod; 2008 Jan; 23(1):1-3. PubMed ID: 18029343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On changing a long-term clinical trial midstream.
    Wittes J
    Stat Med; 2002 Oct; 21(19):2789-95. PubMed ID: 12325094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The statistician and the data monitoring committee.
    D'Agostino RB
    Stat Med; 2004 May; 23(10):1501-2. PubMed ID: 15122726
    [No Abstract]   [Full Text] [Related]  

  • 40. Early viewing of noninferiority trials in progress.
    Dignam JJ
    J Clin Oncol; 2005 Aug; 23(24):5461-3. PubMed ID: 16027438
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.